Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

UnitedHealth reports 3 months of 2023

4/14/23 UNH

BlackRock reported for 3 months of 2023

4/14/23 BLK

Ozon will launch a local marketplace in Kyrgyzstan

4/14/23 OZON

Board of Directors of Ryazan Energy Supply Company recommended that dividends be paid for 2022

4/14/23 RZSB

Bashinformsvyaz reported for 2022 according to IFRS

4/14/23 BISVP

Rostelecom placed CFA for ₽750 million on Alfa-Bank's platform

4/14/23 RTKM

Kovrov Mechanical Plant reported for 3 months of 2023 according to RAS

4/14/23 KMEZ

The Dow announced a quarterly dividend

4/14/23 DOW

EL5-Energo reported for 2022 according to IFRS

4/13/23 ELFV

Novatek asked to target the resource base for LNG projects

4/13/23 NVTK